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Abstract 
 Anthracyclines are widely used in patients for anticancer activity. However, one 
of the limitations for their clinical use is P-gp-mediated drug resistance in cancer therapy. 
We hypothesize that modified anthracyclines will retain their anticancer activity, avert P-
gp binding, and thus overcome P-gp-mediated drug resistance. Twenty-five daunorubicin 
analogues were synthesized with slight structure modifications in sugar moieties. 
Molecular docking, cytotoxicity, and P-gp inhibition assays in drug-resistant leukemia 
cells (K562/Dox) were used to identify several candidates that avert binding to 
multidrug-resistant protein (MsbA) and overcome drug resistance. Molecular docking 
showed that daunorubicin bound to the cavity between the intracellular domain (ICD) and 
nucleoside binding domain (NBD) of MsbA, which might be the “entry site” for the 
transport of its substrate. The molecular docking accurately predicted the substrates of 
multidrug-resistant protein. Several aspects are important for daunorubicin analogue 
binding to MsbA: (1) the substitution pattern and stereochemistry of the tetracyclic ring 
and sugar moiety; (2) the hydrogen bond donor or acceptor capability of the substituent at 
C`-3 and C`-4. Molecular docking, cytotoxicity, and P-gp inhibition assays identified 
ADNR, ADNR-1, and ADNR-3 for averting P-gp binding and overcoming drug 
resistance. The replacement of C`-3-NH2 with azido group in daunorubicin not only 
abolishes the hydrogen bond between the sugar moiety and MsbA but also completely 
changes the overall binding conformation, and thus averts the binding to MsbA. 
Cytotoxicity assays confirmed that these compounds showed high sensitivity against 
drug-resistant cancer cells (K562/Dox) with P-gp over-expression. P-gp inhibition assay 
indeed confirms that these appropriately modified compounds avert P-gp binding and 
thus overcome P-gp-mediated drug resistance. 
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Chapter One 
 
Problem Statement 
 
 The anthracycline antibiotics daunorubicin, doxorubicin, idarubicin, and 
epirubicin are potent anti-cancer drugs used in cancer chemotherapy.  Unfortunately, 
their clinical success is limited by two factors: multidrug resistance and cardiotoxicity.  
This proposal and subsequent experiments will seek to determine the effectiveness of 
new daunorubicin derivatives in averting multidrug resistance.  Additionally, we will 
ascertain the mechanism of action of new anthracycline derivatives.  MDR is one of the 
major threats to successful anti-neoplastic chemotherapy.  MDR is often mediated by P-
gp, which exports anthracyclines and other drugs from the cell.  An anthracycline which 
can overcome P-gp related MDR would greatly improve chemotherapy success and 
enhance the overall and cancer-free survival rates of chemotherapy patients. 
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Introduction  
 Multidrug Resistance (MDR) is a mechanism that cancer cells use to evade the 
cytotoxic effects of chemotherapeutic drugs.  MDR can be an inborn property of a cancer 
cell, or induced by a chemotherapeutic drug.  It is important to note that MDR cells show 
decreased sensitivity not only to the drug which induced the resistance, but to a broad 
panel of drugs which often show no structural or functional similarity [1].  Currently drug 
resistance to chemotherapy is believed to cause failure in over 90% of patients with 
metastatic cancers [2].   Drug resistance to chemotherapy is mediated by a variety of 
biological pathways.  Drug efflux, drug inactivation, and pro-survival (anti-apoptotic) 
signaling seem to be among the most prominent of the mechanisms by which cancer cells 
avert death due to chemotherapy.  The simplest and most efficient mechanism of drug 
resistance is drug efflux, therefore, the synthesis of compounds which are effective anti-
neoplastic agents which overcome efflux-mediated resistance is of great importance [3].  
 Although anthracyclines are among the most effective anticancer drugs in use 
today, either as single agents or in combination therapy, multidrug resistance of 
anthracyclines is one of the limitations for the clinical use of these drugs.  Multidrug 
resistance of anthracyclines is considered to be mediated by the efflux pump of the 
products of multidrug resistance genes family.    
 Efflux-mediated MDR is generally characterized by an over-expression of one or 
several members of the ATP-Binding Cassette (ABC) transporter family.  There are now 
48 known ABC transporter genes organized into seven subfamilies (ABCA-ABCG) [4]. 
ABC transporters efficiently export a broad variety of cytotoxic drugs from the lipid bi-
layer, on which they reside [5].  Acting as pumps, these proteins function by exporting a 
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broad range of lipophilic molecules [4].  These proteins are commonly found in high 
levels to remove harmful xenobiotics and metabolites in the healthy tissues of the lungs, 
kidney, digestive tract, liver, as well as the blood-brain, blood-testis and blood-placental 
barriers [6].  In cancer cells these proteins are overexpressed and function to export 
anticancer drugs such as anthracyclines from cells.  This decreases intracellular drug 
concentrations, diminishing the chemotherapeutic effectiveness and thus conferring drug 
resistance.     
 The multidrug resistance of anthracyclines is mediated by P-glycoprotein (P-gp), 
the product of the MDR1 (ABCB1) gene.  MDR cell lines are often shown to over-
express P-gp, which is correlated with anthracycline resistance in vitro [2]. P-gp, like 
other members of the ABC transporter family is predicted to have a 6+6 helical structure. 
Its tertiary structure appears as a roughly hexagonal toroidal ring [7].  The protein 
requires hydrolysis of two molecules of ATP to transport one drug molecule (or other 
molecule) out of the cell.   
 The mechanism of P-gp transport has been well characterized [8, 9], however the 
crystal structure of mammalian P-gp still remains to be solved.  The lack of crystal 
structure of P-gp makes it difficult to study the substrate binding and to design the new 
drugs to overcome P-gp. Recently, Chang et. al. have been able to solve the crystal 
structure of an ABC transporter, MsbA, from bacteria [10-12].  The amino acid sequence 
of MsbA is 36% identical to that of P-gp.  MsbA forms a homodimer as the functional 
transporter, and each subunit has six transmembrane domains and one ATP binding 
domain [10-13].  More importantly, MsbA is also in the ABC family of multidrug 
resistance protein and confers drug resistance in bacteria.  Furthermore, MsbA and P-gp 
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share many common substrates.  Thus,  the MsbA model may be used to explain the 
transport activities of the ABC transporter family in general [11], especially because the 
two transmembrane domains of both contain 6 alpha-helical segments that comprise the 
substrate transporting channel [8, 11, 14].  
 Daunorubicin is one of the anthracyclines used clinically against leukemia.  
Daunorubicin features tetracyclic-ring structure and an amino sugar (daunosamine).  The 
tetracyclic ring functions to intercalate DNA, while the sugar moiety functions as the 
minor groove binder of DNA.  In addition, the sugar moiety may also interact with its 
molecular target, topoisomerase II [15-17].  Two major side effects are associated with 
the clinical use of daunorubicin: cardiotoxicity and multidrug resistance.  
 Previous work [18, 19] shows not only that a structure activity relationship exists 
between the sugar moiety and drug activity, but that the sugar plays a crucial role in the 
effectiveness of the drug.  However, this relationship is neither clear, nor well understood.  
Circumventing P-gp-mediated resistance is especially difficult due to the necessity of 
preserving the cytotoxic activity [20].  It has been shown that modifying the sugar moiety 
in daunorubicin can change the anticancer efficacy of anthracyclines [21-23].  In addition, 
the 3’-amino group in the sugar may also play a role for P-gp recognition [24, 25].  
Therefore, we hypothesize that modifying the sugar moieties of anthracyclines will retain 
its anticancer activity, alter their ability for binding to P-glycoprotein (P-gp), and thus 
overcome P-gp-mediated multidrug resistance (MDR). 
 We have previously synthesized a series of daunorubicin analogs with sugar 
modifications as a chemical biology tool.  The molecular docking was used to identify 
the binding configuration of new analogs to MsbA, a homolog of P-gp.  The molecular 
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docking results were confirmed by the anticancer activity in drug-sensitive and drug-
resistant leukemia cells.  Several candidates were identified to avert P-gp binding and 
overcome P-gp-mediated drug resistance. 
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Objectives 
 
 To find an effective treatment which overcomes P-gp-mediated MDR we have 
synthesized and tested 25 daunorubicin analog molecules.  Each of these molecules 
contains a naturally occurring uncommon 2,6-dideoxy sugar conjugated to the ring 
structure of anthracyclines.  There will be two specific aims of this study.  The hypothesis 
pivotal to these aims is that by modifying the sugar moiety of daunorubicin the new 
analog will no longer be a P-gp substrate, and will therefore reduce drug resistance which 
will improve chemotherapy success. 
Aim One:  The primary aim of this study is to examine the effectiveness of these 
compounds (Figure 1) in overcoming P-gp mediated resistance in leukemia and/or solid 
tumor cells, and thus determine their possible efficacy as the possible next generation of 
anthracyclines.   
Aim Two:  Should we find one or more drugs which show promise in overcoming 
multidrug resistance, we will then study the biological mechanism by which these drugs 
avert MDR.  Specifically, we seek to confirm that the drug overcomes MDR by averting 
P-gp mediated resistance.  
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Chapter Two 
 
Methodology/Design 
 
Synthesis and structures of 25 anthracycline analogs with sugar modification 
 We have previously synthesized 25 daunorubicin analogs with sugar 
modifications [22, 23, 26, 27]. To study the uncommon sugar function in anthracyclines, 
four different groups of anthracyclines with various uncommon sugars as 
monosaccharides or disaccharides were synthesized (Fig 1).  
 The first group of daunorubicin monosaccharides (compounds DNR-1 – DNR-6) 
were stereoselectively synthesized using TTBP/AgPF6 glycosylation. The second group 
of daunorubicin analogs were synthesized with disaccharides (compounds DNR-D1 – 
DNR-D8). Based on the molecular docking results as discussed below, we synthesized 
the third group daunorubicin analogs with azido sugar or triazole sugars (compounds 
ADNR, ADNR-T1 – ADNR-T4).  The fourth group of daunorubicin analogs was an 
attempt to optimize the lead compound (ADNR). (Fig. 1) 
     
 
Molecular Docking of daunorubicin analogs to MsbA  
 Since no crystal structure of mammalian P-gp is available the crystal structure of 
MsbA with 3.8 Å resolution, an ortholog in bacteria, was used for docking study [28]. 
MsbA has 36% homology to human P-gp. MsbA and P-gp also have common substrate 
specificity and function in the same manner.    
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Preparation of MsbA  
 MsbA (PDB ID: 1PF4) was chosen for the docking template.  The functional 
binding pocket was selected using Sybyl version 7.1.  Polar hydrogens were added and 
Kollman charges assigned to the selected binding pocket.  3-D affinity grids covering the 
entire binding pocket were calculated for each of the following atom types: C, A 
(aromatic C), N, O, H, and e (electrostatic) using Autogrid3.   
Preparation of ligands and docking 
 For the ligands, all hydrogens were added and Gasteiger charges were assigned, 
after which the non-polar hydrogens were removed.  The rotatable bonds were assigned 
via AutoTors.  AutoDock version 3.0.7 was used for the docking simulation. For each 
compound, the docking parameters were as follows: trials of 50 dockings, random 
starting position and conformation, rotation step ranges of 50º, and 1 million energy 
evaluations.  Autodock Tools was used to evaluate the binding conformations to select 
the conformation of best fit.  Chimera was used to describe hydrogen bonding and to 
generate the images. 
 
IC50 determination of daunorubicin analogs in drug-sensitive (K562) and drug-
resistance leukemia cells (K562/Dox)  
 The drug sensitive leukemia cells (K562) were cultured in RPMI-1640 containing 
10% fetal bovine serum, 1% Penicillin/Streptomycin, and 1% L-glutamine. The medium 
was replaced every two to three days. Drug resistant leukemia cells (K562/Dox) were 
induced for drug resistance by incubation of K562 with doxorubicin for more than 3 
months. K562/Dox was cultured in RPMI-1640 medium with 0.5 uM doxorubicin.  
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Before each experiment, K562/Dox cells were stimulated with 0.1 µM doxorubicin at 
least for one week and then cultured for 10 days without doxorubicin stimulation. It was 
assured that P-gp expression level was similar in every experiment. The cells were 
cultured in a 37 degrees Celsius humidified incubator with an atmosphere of 5% CO2.     
 A total of 2,000-5,000 cells (K562 and K562/Dox) were seeded in 96-well plates 
and incubated for 24 hours.  Synthetic compounds were added in a series of dilutions (0.1 
nM – 10 µM) and incubated for 3 days.  After 3 days, MTS (3-[4,5-dimethylthiazol-2-yl]-
5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium), and phenazine 
methosulfate (PMS, an electron coupling reagent which allows the metabolization to 
proceed) were added directly to the cell culture and incubated for 1-4 hours at 37°C in a 
humidified, 5% CO2 atmosphere.  The MTS/PMS mixture is metabolized by living cells 
into formazan.  The absorbance of formazan (metabolite of MTS in viable cells) is 
measured at 490 nm.  Because the absorbance value of formazan has a linear correlation 
to the number of viable cells in each well, the absorbance value is used to calculate the 
surviving cell fraction.  The IC50 values against drug-sensitive and drug-resistant cells of 
the tested compounds were calculated with dose-response curves using WinNonlin.  The 
Drug Resistance Index (DRI), which is the ratio of IC50 in K562/DOX compared to IC50 
in K562, was calculated.  
 
P-gp inhibition assay using CsA for daunorubicin analogs  
 A simple and rapid high throughput P-gp inhibition assay was used to validate P-
gp substrates.  Co-incubation of P-gp inhibitor (Cyclosporine A, CsA) blocks P-gp 
exporter function, increases intracellular concentration of daunorubicin analogs, and 
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therefore increases the cell killing effects of daunorubicin.  Therefore, the P-gp inhibition 
can be quantified by the high throughput MTS assay by comparison of the cell killing 
effects of daunorubicin analogs in the presence or absence of CsA.  Total of 2,000-5,000 
cells (K562/Dox) were seeded in 96-well plates and cultured for 24 hrs.  The cells were 
pretreated with 5 µM Cyclosporine A (CsA) for 10 minutes. Then the synthesized 
compounds (1 µM) were added. After 72 hours, tetrazolium [3-(4,5-dimethythiazol-2-
yl)]-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS, 2 
mg/ml) and phenazine methosulfate (PMS, 25 µM) were mixed and added directly to the 
cells. After incubated for 3 hrs at 37 °C, the absorbance of formazan (the metabolite of 
MTS by viable cells) was measured at 490 nm.  
 
Expression levels of P-gp in drug-resistant leukemia K562/Dox  
 Total RNA isolation and cDNA synthesis:  Total cellular RNA was extracted and 
purified using the TRIzol reagent (Gibco). The pellet was resuspended in 30-50 ul of 
DNase/RNase free-water, and the concentration was measured at 260 nm UV. First-
strand cDNA was transcribed from 3µg of total RNA using 50ng random hexamers and 
SS II reverse transcriptase was used for reverse transcription at 42°C for 50 min. After 
termination of the reaction, 1µl of RNase H was added to the tube and incubated for 20 
min at 37 °C before proceeding to amplification of the target cDNA. 
 Real-time PCR:  SYBR Green PCR Master Mix was purchased from Applied 
Biosystems. Forward and reverse primers for targeted mRNA were designed using Primer 
Express version 1.0 software (ABI PRISM, Perkin-Elmer, Branchburg, NJ) based on the 
human MDR1 or actin sequence. The real-time PCR was completed on the ABI PRISM 
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Sequence Detector 7000 (Perkin-Elmer) using Sequence Detector version 1.7 software. 
The PCR was performed at 95 °C for 15 seconds, primer annealing and extension at 60 
°C for 1 minute.  Fold reduction of siRNA knockdown was calculated as follows: after 
completion of the PCR, the baselines and thresholds were set for both samples and 
internal beta-actin controls. Using Ct values (cycle number where sample crosses the 
threshold value) for samples (sam) and controls, the ∆Ct was calculated: ∆Ct = Ctsam – 
Ctactin. Then the values for each sample (sam) were compared with the negative siRNA 
control (neg): ∆∆Ct = ∆Ct sam - ∆Ct neg.  The fold change of mRNA level from negative 
control to sample is 2-∆∆Ct.  MDR1 level in K562/Dox was compared to K562.  
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Population and Sample 
 
 For the purpose of identifying a compound which is useful against both sensitive 
and MDR cells we must use cells of each type.  For the sensitive leukemia cell line we 
will use K562 cells.  For the resistant leukemia cell line we will use K562/Dox cell line (a 
gift from J.P. Marie, INSERM, E9912, University of Paris, France) which has been made 
resistant to anthracyclines.  The K562/Dox cells were stimulated with 0.1 µM 
doxorubicin once a month to maintain their resistance.   
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Data and Instrumentation 
 The data collected from the MTS assays will be the absorbance readings, which is 
directly proportional to the number of cells (gives a linear curve with slope =1).  
Therefore the absorbance reading will be mathematically converted into a viable cell 
count (as a percentage of the control group).  For measuring the absorbance at 490nm, a 
Molecular Devices Spectromax Plus384 Microplate Spectrophotometer will be used. 
 The molecular docking simulations were performed by AutoDock version 3.0.7 
with ligands and proteins prepared by Sybyl version 7.1.  This work was done on a 
Silicon Graphics SGI02. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Robert F. Battisti 
Page 17 of 48 
Chapter Three 
Results  
 
Molecular Docking of Daunorubicin Analogs to MsbA 
 
 We hypothesize that the structure modification of daunorubicin will change the 
binding to P-gp and overcome P-gp-mediated drug resistance. Therefore, we first utilized 
molecular docking to test our hypothesis with 25 daunorubicin analogs with series 
modifications on the sugar moiety.  However, no crystal structure of mammalian P-gp 
was available.  Fortunately, a distant ortholog (MsbA) in bacteria, which has 36% 
homology to human P-gp, has been crystallized with 3.8 Å resolution [10-12].  More 
importantly, MsbA is also in the ABC family of multidrug resistance protein and share 
common substrate specificity to confer drug resistance in bacteria. Therefore, molecular 
docking (Autodock version 3.0.7) was performed for daunorubicin analogs against MsbA 
to test our hypothesis. A summary of each compound’s binding energy to MsbA can be 
found in Table 1.  The docking results are shown in Figures 3-8. 
 Daunorubicin 
 
 The molecular docking results showed that daunorubicin (DNR) favorably bound 
to the cavity between the intracellular domain (ICD) and nucleoside binding domain 
(NBD) of MsbA (Fig 2A). C-6-OH of DNR had hydrogen bonding to the Asn436 in the 
NBD α2 domain of MsbA.  The C’-4-OH of the sugar in DNR formed hydrogen bond 
with His107 in ICD1 domain, while C’-3-NH2 interacted with His202 in the ICD2 
domain and Asp431 in the NBD α2 domain of MsbA (Fig 2B).  This gave the docked 
complex a favorable binding energy of -7.92 kcal/mol.  The strong hydrogen bonds, 
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coupled with low energy values showed that DNR is indeed a substrate of this multidrug 
resistance protein (Fig 2).    
 This binding configuration may have an important indication. It is generally 
believed that ABC transporters export their substrates via the “funnel” like cavity in the 
center through a conformation change. It is hypothesized that from here the transporting 
of the substrates is dynamic as the drug is moved from the cytoplasm, through the 
membrane into the periplasm [28].  In such a case, the substrate should not bind tightly to 
the center cavity in order for the transporting to occur. However, the substrate has to bind 
the transporter protein at an “entry site” in order for the protein to recognize the substrate.  
The challenge at this point is to find where this “entry site” located.  Interestingly, within 
the cytoplasmic portion of MsbA there exists a cavity or pocket within the tertiary 
structure of each monomer between the intracellular domain and nucleotide binding 
domain.  The docking results showed that daunorubicin binds to this cavity (Fig 2B). 
This may suggest that daunorubicin comes to the transporting cavity via this “entry site.” 
It appears that the binding to the “entry site” is crucial for determining whether or not a 
compound is a substrate of MsbA.   
 DNR monosaccharide analogs  
 
 To vary the structure of daunorubicin to overcome P-gp, we synthesized the DNR 
monosaccharide analogs with monosaccharides linked to the tetracyclic ring structure of 
anthracycline via a beta glycosidic linkage (DNR-1 to DNR-6).  Molecular docking 
results showed that DNR-1, DNR-2, DNR-3, DNR-4, DNR-5, and DNR-6 all have 
favorable binding to MsbA with binding energy of -9.05, -8.80, -9.20, -8.13, -8.15, and -
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7.50 kcal/mol, respectively. These results indicate that DNR-1 to DNR-6 may still be P-
gp substrates (Fig 3).   
 The binding conformation of DNR-1 to DNR-4 was similar to daunorubicin (Fig. 
3A, 3B).  The glycosidic linkage oxygen and the keto group at C-5 of DNR-1 – 4 formed 
hydrogen bond with Asn436 and Phe429 in the α2 and the hinge region between β4 and 
α2 regions of the NBD domain of MsbA.  Although the C’-3- NH2 group in the sugar 
was replaced with C’-3-OH, or C’3-OMe, they still have hydrogen bond donating and 
accepting ability to form hydrogen bonds or favorable electrostatic interactions with 
His202 in the ICD2 domain.  Some subtle differences in hydrogen bonding occurred, for 
example DNR-2 and DNR-3 did not exhibit true hydrogen bonding, but are probably 
stabilized by favorable electrostatic interactions between the C’-3 groups and His202.  
DNR-1 was further stabilized by a hydrogen bond from the C’-3-OH of DNR to Tyr439 
of the α2 region of MsbA. These data suggest that the hydrogen donor or acceptor on C’-
3 or C’-4 position may be critical to determine the binding of daunorubicin analogs to 
MsbA.  
 Therefore, we removed the C3’-OH in the sugar of DNR-5. However, DNR-5 still 
favorably bound to MsbA with -8.16 kcal/mol binding energy (Fig 3C). The favorable 
binding may come from the hydrogen bond between the keto group and glycosidic 
oxygen of DNR-5 and Asn436 and Phe429 in the α2 and the hinge region between 
β4 and α2 regions of the NBD domain of MsbA.   
 Furthermore, we replaced all polar group from the sugar structure of DNR-6 and 
added a high electron density group (azido, N3) on C’-4.  Although these modifications 
significantly changed the binding conformation of DNR-6 to MsbA as compared to DNR, 
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DNR-6 still favorably bound to MsbA with binding energy of -7.50 kcal/mol. The 
glycosidic linkage oxygen and the keto group at C-5 still formed hydrogen bond with 
Asn436 and Phe429 in the α2 and the hinge region between β4 and α2 regions of the 
NBD domain of MsbA (Fig 3D).  
 These results suggest that both the tetracyclic ring and sugar moiety of 
daunorubicin contribute the binding to MsbA. In addition, the substitution pattern and 
stereochemistry of the tetracyclic ring and sugar moiety play an important role for 
daunorubicin analogs to fit into the binding cavity of MsbA (Fig 3). 
    
 DNR Disaccharide analogs  
 In order to introduce more structure variability in the DNR analogs, we 
synthesized eight daunorubicin analogs with disaccharides (DNR-D1 to DNR-D8), in 
which the first sugar remained the same as DNR, but various second sugars are linked to 
the C’-4 position of the first sugar.  Both alpha and beta glycosidic linkages were 
synthesized (Fig 1).  Surprisingly, all eight analogs favorably bound to MsbA in a similar 
configuration as daunorubicin (Fig 4), and with relatively similar binding energy (ranging 
from -7.8 kcal/mol to -11.2 kcal/mol).  
 Each DNR disaccharide analog forms hydrogen bonds from the C’-3-NH2 group 
to His 202, from the first glycosidic oxygen to Asn436, and from the C-5 keto group to 
Phe429 (Fig 4A, 4B, 4C, 4D).   Exceptions are DNR-D1 and DNR-D6 which did not 
form a hydrogen bond to Asn436. Interestingly, DNR-D4 and DNR-D7 had hydrogen 
bonding to Cys315 from the C’’-3-OH group of the second sugar (Fig 4C).  
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 These results strongly suggest that the first sugar moiety of daunorubicin analogs 
plays a more important role for the binding of MsbA. Addition of the second sugar does 
not significantly change the binding conformation to MsbA. It appears that it is difficult 
to avert the binding to multidrug resistant protein without altering the first sugar moiety 
of daunorubicin (Fig 4). 
      
 ADNR analogs 
 Based on the information of the above docking results, it seems that several 
aspects are important for daunorubicin analogs binding to MsbA: (1) both sugar moieties 
and tetracyclic ring structure of daunorubicin; (2) C’-3 and C’-4 hydrogen bond donor or 
acceptor capability; and (3) the overall structure conformation of daunorubicin analogs 
that determined by the tetracyclic rings and sugar structure.  
 The binding conformation of DNR-6 to MsbA, in which C’-4-N3 group in the 
sugar moiety was able to significantly alter the whole binding conformation of DNR-6 to 
MsbA as compared to DNR.  In addition, C’-3-NH2 group has been reported to be 
critical for P-gp binding [14, 29].  Therefore, we hypothesize that replacement of C’-3-
NH2 group with an azido group or large triazole group may be able to change both the 
binding conformation and/or abolish the hydrogen bond between DNR and MsbA. Thus, 
ADNR and ADNR-T1 to ADNR-T4 were synthesized to test our hypothesis [22].   
 Very interestingly, ADNR bound unfavorably to MsbA compared to DNR. Its 
binding energy (+2.94 kcal/mol) is significantly higher than that of DNR. This 
modification completely changes the overall conformation of the ADNR binding to 
MsbA. The tetracyclic rings of DNR and ADNR are roughly perpendicular to each other.  
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The sugar modification in ADNR completely abolished the hydrogen bond between C’-3 
and MsbA. The only hydrogen bonds between ADNR and MsbA are glycosidic oxygen 
of ADNR to Asn436 and the C’-4-OH group of ADNR to Asp431 of MsbA (Fig 5A). 
These data suggest that ADNR may not favorably bind to multidrug resistant protein and 
may overcome P-gp mediated drug resistance.  Indeed, these findings were confirmed by 
experimental data as show below.  
 Similarly, the DNR triazole analogs (ADNR-T1 to ADNR-T4) also unfavorably 
bind to MsbA with binding energy of + 3.35 to +18.78 kcal/mol (Fig 5B, 5C, 5D).  
Similar to ADNR, ADNR-T1 to ADNR-T4 significantly changed the binding 
conformation to MsbA, abolished the hydrogen bonds between C’-3 with MsbA. The 
only existing hydrogen bond is between the C’-4 hydroxyl group and Cys315 of MsbA.   
 These results indicate that replacement of C’-3-NH2 amino group with azido or 
triazole group sufficiently avert P-gp binding and overcome drug resistance. Although the 
tetracyclic rings of azido sugar analogs and triazole analogs remain the same as DNR, it 
appears that azido or triazole group not only abolishes the hydrogen bond between the 
sugar moiety and MsbA, but also significantly changes the conformation of whole 
structure of DNR. These two important changes are critical to avert the binding to MsbA.  
(Fig. 5) 
     
ADNR disaccharide analogs 
 To further optimize the lead compound ADNR, we synthesized ADNR 
disaccharide analogs (ADNR-1 to ADNR6) with a second sugar linked to first azido-
Robert F. Battisti 
Page 23 of 48 
sugar via beta-linkage.  This was to study the contribution of the second sugar for MsbA 
binding and anticancer activity.  
 Although all six analogs were derived from ADNR with azido-sugar, not all six 
analogs have similar binding to MsbA as compared to ADNR. Similar to ADNR, ADNR-
1, ADNR-3, and ADNR-6 showed unfavorably binding to MsbA with binding energy of 
+ 2.38 kcal/mol to +17.25 kcal/mol (Fig 6). Very surprisingly, ADNR-2, ADNR-4, and 
ADNR-5 regained favorable binding to MsbA with binding energy of -8.92, -7.51, and -
3.22 kcal/mol, respectively (Fig 7). The introduction of second sugar has generated more 
hydrogen bonding between these analogs and also changed the overall binding 
conformation.   
 In fact, the sugar structure of ADNR-1 and ADNR-3 are in completely opposite 
orientation compared to DNR, while the sugar structure of ADNR-6 is very dissimilar.  
No H-bond interaction was found between the sugar structure of these three compounds 
and MsbA. The only hydrogen bonds were found between C6-OH of ADNR-1 and 
His107 of MsbA, and between C-11-OH, C-12-O of ADNR-3 and Cys315, and between 
the C-11 hydroxyl group of ADNR-6 with Cys315 of MsbA. Clearly, the overall 
conformation change and the abolition of critical hydrogen bonding between the sugar 
and MsbA created an unfavorable binding (Fig 6).   
In contrast, a second sugar in ADNR-2, ADNR-4, and ADNR-5 introduced the 
extra hydrogen bond or generated a favorable binding conformation. Although ADNR-2 
showed different binding configuration with MsbA, the introduction of second sugar in 
ADNR-2 re-configured the compound in such a way that the C’’-4-OH group of the 
second sugar interacted with Thr198 in ICD2 domain. Meanwhile the C’-9 hydroxyl 
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group of ADNR-2 regained H-bond interaction with Arg127 in ICD1 domain. These data 
suggest that ADNR-2 still weakly binds to multidrug resistant protein which confers drug 
resistance, which was confirmed by experimental data below. ADNR-4 and ADNR-5 
have dissimilar configurations in relation to DNR.  ADNR-4 forms hydrogen bonds to 
Cys315 from both the C-11 and C-12 hydroxyl and keto groups. The tetracyclic rings of 
the two compounds are nearly perpendicular to each other in docked conformations.  
Although no extensive hydrogen bonds between the second sugar of ADNR-4 (orADNR-
5) and MsbA, the overall conformation of the structure orientated the molecules in such a 
way that they are fitting very well into the binding pocket (Fig. 7).  
These data confirm that the C’-3-NH2 in the first sugar of DNR, tetracyclic ring 
structure, and the overall conformation (determined by tetracyclic and sugar structure) of 
daunorubicin are critical to determine the binding to MsbA. The replacement of C’-3-
NH2 group with an azido group not only abolishes the hydrogen bond between the C’-3 
of the sugar moiety and MsbA, but also completely changes the overall conformation of 
DNR, and thus averts the binding to MsbA.  The second sugar moiety in the sugar 
structure may not be important in overcoming MsbA binding.  Rather, the introduction of 
second sugar sometimes introduces new hydrogen bond or change the overall 
conformation to fit the binding pocket. However, the introduction of the second sugar 
may change the anticancer activity and topoisomerase activity (data not shown) (Fig 6 
and 7).   
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Expression levels of P-gp in drug-resistant leukemia cells (K562/Dox) compared to 
drug sensitive cells (K562) 
 
 To confirm our hypothesis and molecular docking results, we tested the 
cytotoxicity in drug-sensitive leukemia cells (K562) and drug-resistant leukemia cells 
(K562/Dox). First we tested the P-gp expression levels in these two cell lines using real-
time PCR. As shown in Figure 9, the mRNA levels of MDR1 gene were more than 500-
fold in K562/Dox cells compared to K562. Therefore, K562/Dox will show high drug-
resistance for anthracyclines due to the P-gp export function as shown below. That is why 
K562/Dox was used to test the drug cytotoxicity and drug resistance of our daunorubicin 
analogs. (Fig 8) 
 
 
Cytotoxicity and drug resistance of daunorubicin analogs in drug-sensitive and 
drug-resistant leukemia  
 
 MTS Assays were utilized to asses the cytotoxicity in both K562 and K562/Dox 
leukemia cells. These were to confirm if the molecular docking results are in agreement 
with the anticancer activity in drug-resistant leukemia cells (K562/Dox). The cells were 
incubated with varying amounts of drug to give a dose-response curve.  The IC50 of 
daunorubicin analogs were determined by WinNonlin 4.1.  Drug Resistance Index (DRI) 
was calculated by the ratio of IC50 in the drug-resistant K562 vs. IC50 in the drug 
sensitive index. These data are summarized in Table 2. 
 Although daunorubicin showed very sensitive cell killing effects in K562 cells 
with IC50 of 16 nM, it indeed exhibited drug resistance in K562/Dox due to the high 
levels of P-gp expression. The drug resistance index is greater than 320.   
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DNR monosaccharide analogs 
 The MTS results showed that all the DNR monosaccharide analogs (DNR-1 to 
DNR-6) exhibit very high IC50 in K562/Dox and none of them overcame drug resistance 
against drug-resistant K562/Dox compared to DNR. This data set is in agreement with 
molecular docking results that none of these analogs averted binding to multidrug 
resistant protein MsbA.  In addition, it is important to note that since sugar modifications 
in DNR-2, DNR-3, and DNR-6 even resulted in the loss of anticancer activity in drug-
sensitive cells, the drug resistance index (DRI) can not be calculated for the confirmation 
of the P-gp substrate. 
  DNR disaccharide analogs 
 DNR disaccharides (DNR-D1, -D2, -D3, -D5, -D8) slightly improved cytotoxicity 
against drug-resistant K562/Dox compared to DNR. However, the drug resistance index 
(DRI) is still relatively high (>50). It is also important to note that the cytotoxicity of 
these compounds may dependent on two factors: drug efflux pump and drug target 
topoisomerase. Whether these compounds may overcome drug resistance needs to be 
further confirmed with the experiment below (P-gp inhibition Assays).  It is also worth 
noting that DNR-D4, DNR-D6, and DNR-D7 lost their activity in both drug-sensitive and 
drug-resistant cells due to the lack of topoisomerase II poisoning (data not shown). 
Therefore, DRI is not used to confirm the P-gp substrates.  
 DNR azido sugar (ADNR) and triazole sugar (ADNR-T1 to -T4) analogs 
 Very interestingly, ADNR with azido sugar significantly reduced the IC50 against 
drug-resistant cells compared to DNR. The drug resistant index (DRI) significant reduced 
to less than 13.  Together with the molecular docking results that ADNR may avert 
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binding to MsbA; these data may suggest that ADNR overcome P-gp-mediated drug 
resistance in cancer cells. In contrast, although ADNR-T1 to T4 also avert MsbA binding 
by molecular docking, these four compounds also lost their activity against both drug-
sensitive and drug-resistant cancer cells. The lost activity is due to the lack of 
Topoisomerase II poisoning (data not shown). Thus, the DRI is not used to confirm the p-
gp substrates for ADNR-T1 to –T4.  
 ADNR disaccharide analogs 
 Although the disaccharide reduces the sensitivity of ADNR-1 to ADNR-6 in 
drug-sensitive cells, these compounds indeed showed high sensitivity against drug-
resistant leukemia cells (except for ADNR-2 and ADNR-4). The drug resistance indexes 
(DRI) were indeed significantly decreased compared to DNR. These results suggest that 
these compounds (ADNR-1, -3, -5, -6,) may overcome drug resistance.  The molecular 
docking results indeed showed that ADNR-1, ADNR-3, and ADNR-6 indeed averted 
MsbA binding while ADNR-2 and ADNR-4 showed favorable binding to MsbA. The 
agreement of these results for compounds (ADNR-1, -2, -3, -4, and -6) and the 
discrepancy for ADNR-5 need to be further tested in the following experiments.    
 Molecular docking energy can qualitatively distinguish the P-gp substrate  
 By analyzing the molecular docking energy of these daunorubicin analogs to 
MsbA, it is very important to note that there is no simple correlation between associated 
binding energy and DRI.  However, our docking method can accurately predict whether 
or not a compound is a P-gp substrate.  Analyzing tables 1 and 2, it can be shown that our 
docking model alone was accurate in predicting relative DRI for all but one (ADNR-5) or 
our 25 compounds.  Each favorably docking compound (with binding energy less than 0) 
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shows a DRI of 12 or more, with the one exception of ADNR-5 (or is inactive), while 
each unfavorably docking compound (with binding energy great than 0) shows a DRI of 
5 or less (or is inactive).  This data implies that molecular docking may provide an 
accurate means of analyzing the ability of compounds to overcome p-gp-mediated MDR. 
P-gp inhibition assay 
 In order to further confirm the molecular docking results and P-gp-mediated drug 
resistance in drug-resistant cancer cells (K562/Dox), we used a combination of P-gp 
inhibition and MTS assay to distinguish whether daunorubicin analogs avert P-gp binding 
and overcome drug resistance.   If a daunorubicin analog is a P-gp substrate, it will be 
exported from the K562/Dox cell by overexpressed P-gp, and thus it will have lower 
intracellular concentration to confer drug resistance.  When a P-gp substrate (such as 
daunorubicin) is incubated with P-gp inhibitor (cyclosporine, CsA) in K562/Dox, CsA 
will competitively inhibit P-gp and block the export function.  Thus, CsA will 
significantly increase the intracellular concentration of the P-gp substrates (such as 
daunorubicin) to exhibit much higher cell killing effects against K562/Dox. In contrast, 
CsA will not change the cytotoxicity of non-P-gp substrates.  However, it is worth noting 
that if daunorubicin analogs lost their anticancer activity (due to the lack of 
topoisomerase II poisoning), this experiment can not be used to distinguish the P-gp 
substrate and can only be used as a negative control.   
 As shown in Fig 10A, when 1 uM daunorubicin was incubated with 5 uM of CsA 
in K562/Dox, the cell killing effects increased by 2.25-fold although CsA alone (5 uM) 
did not show any cytotoxicity.  These results indeed confirm the molecular docking 
results and strongly suggest that daunorubicin is indeed a P-gp substrate.  
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 In DNR monosaccharide analogs, CsA also significantly increased the cell killing 
effects of DNR-1, DNR-4, and DNR-5 by 1.61 to 3.05-fold.  These data also confirm the 
molecular docking results and suggest that these compounds are P-gp substrates.  It is 
important to note that DNR-2, DNR-3, and DNR-6 lost their anticancer activity in both 
drug-sensitive (K562) and drug-resistant leukemia (K562/Dox).  Even though CsA did 
not change the cell killing effects of DNR-2, -3, and -6, this experiment can not be used 
to confirm if they are P-gp substrate or not.  These compounds only served as a negative 
control in this experiment.  
 In DNR disaccharide analogs, CsA also significantly increased the cell killing 
effects of DNR-D1, -D2, -D3, -D5, -D8 from 1.85 fold to 5.77-fold, similar to DNR. 
These data together with molecular docking suggest that these compounds are still P-gp 
substrates. Since DNR-D4, -D6, and -D7 lost their anticancer activity, we did not test 
these compounds in this experiment set.  
 As expected, ADNR, ADNR-1, ADNR-3, and ADNR-6 showed anticancer 
effects in both drug-sensitive and drug-resistant leukemia; however CsA did not change 
their cell killing effects in K562/Dox. These results together with molecular docking 
results strongly suggest that these three compounds avert P-gp binding and overcome 
drug resistance.  In contrast, ADNR-2, ADNR-4, and ADNR-5 did show significantly 
high cell killing effects when combined with CsA, which indicate that they may still be 
the substrate of P-gp.  These data also confirmed by the molecular docking results. Only 
some discrepancy was seen for ADNR-4. The molecular docking showed ADNR-4 still 
binds to MsbA, but CsA did not enhance its cell killing effects. The detailed mechanism 
for this discrepancy may warrant further study in the future. 
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Discussion 
 Several strategies have been explored to overcome P-gp-mediated drug resistance. 
The first attempts to circumvent the P-gp efflux were inhibition of P-gp’s ability to export 
the drug via competition for binding and transport.  Cyclosporine A, a known auto-
immune suppressant, and verapamil, a calcium channel blocker, were among the first 
generation of P-gp inhibitors.  By adding these compounds to the regimen of 
chemotherapeutic drugs they will compete for binding and export via P-gp, leading to 
higher intracellular drug concentration of other anticancer drugs.  Thus the compounds 
act as competitive inhibitors of P-gp.  Both of these were used successfully in vitro to 
overcome P-gp mediated resistance.  However, in vivo testing for these drugs in 
combination with anticancer drugs has a variety of detrimental effects.  The first 
generation of P-gp inhibitors required a dose so high that toxic side effects often occurred.  
Second and third generations of these P-gp inhibiting compounds have since been 
synthesized and evaluated in pre-clinical and clinical trials, reaching only modest levels 
of success.  The definitive downfall of the use of these compounds is the fact that a 
variable pharmacokinetic interaction exists in other organs [3].  Therefore, any P-gp 
inhibitor could potentially pose a threat to the normal, healthy tissues of the kidney, lung, 
brain, colon, uterus or adrenal glands which depend on the function of P-gp for the efflux 
of xenobiotics [30].  Given such a long and varied history of problems perhaps small 
compound P-gp competitive inhibition is not the best strategy for overcoming drug 
resistance. 
 A second and more promising strategy for defeating P-gp-mediated MDR is direct 
modification of the structure of anticancer drugs to maintain anticancer activity and avert 
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P-gp binding. As reported here, we have modified sugar structure of anthracycline to 
generate a series of daunorubicin analogs. These analogs were tested to overcome P-gp 
binding by molecular modeling, cytotoxicity, and P-gp inhibition. Indeed, we have 
generated several lead compounds that maintain the anticancer activity and avert P-gp 
binding [23].  In addition, our results have also been confirmed by previous studies. For 
instance, modification of the structure of anthracycline has demonstrated some success in 
overcoming drug resistance [17, 31].  The 3’-amino group in the sugar may plays a role 
for P-gp recognition [24, 25], but it has also been suggested [18] that the amino group 
may stabilize intercalation of DNA.  When the 3’-NH2 of doxorubicin was replaced with 
a 3’-OH or 3’-N-methylation, the resulting compounds partially reversed drug resistance 
[32-40], but were slightly less cytotoxic.  Furthermore, these daunorubicin analogs in our 
study are only slightly modified in their structures. These structures are very similar yet 
several compounds exhibit the capability to overcome P-gp binding and overcome drug 
resistance. Since P-gp is very difficult to study due to the membrane protein nature, the 
daunorubicin analogs provide an excellent means for study P-gp functions using chemical 
biology methods.  For instance, since our molecular modeling have identified the amino 
acid residues in MsbA that interact with daunorubicin analogs and confirmed by the non-
P-gp substrates with similar structure (such as ADNR), this information may well be used 
for further chemical biology study for P-gp for substrate binding sites.   
 It is certainly true that any molecular docking program has limitations.  An x-ray 
crystallography study will always prove to be more definitive and accurate than the best 
docking simulation.  There are many situations, however, where x-ray crystallography is 
not currently feasible.  One of these areas is with membrane proteins such as P-gp.  To 
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validate the accuracy of the molecular docking, cytotoxicity and P-gp inhibition assays 
were used in P-gp overexpressed leukemia cells (K562/Dox).  The cytotoxicity and P-gp 
inhibition assay are in agreement with the molecular docking study.  Although there is no 
simple correlation between associated binding energy and DRI, our docking method can 
qualitatively predict whether or not a compound is a P-gp substrate. This data implies that 
molecular docking may provide an accurate means of analyzing the ability of compounds 
to overcome p-gp-mediated MDR.  Furthermore, while it will be important to support 
modeling data with biological data, future drug design can progress greatly with 
computer modeling. 
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Conclusion 
 In summary, we have studied previously synthesized 25 daunorubicin analogs 
with structure modifications in sugar moieties with the aim to overcome P-gp mediated 
drug resistance. These similar chemical structures provide an excellent probe for 
chemical biology study of P-gp.  Molecular docking, cytotoxicity, and P-gp inhibition 
assay were used to identify several candidates that successfully avert binding to 
multidrug resistance protein and overcome drug resistance.  
 Molecular docking with 25 daunorubicin analogs showed that the cavity between 
the intracellular domain (ICD) and nucleoside binding domain (NBD) of MsbA is the 
binding site for daunorubicin, which might be the “entry site” for the transport of the P-
gp substrate. The amino acid residues His107, His 202, Asp431, and Asn436 are critical 
for the substrates to bind to MsbA.  
 The molecular docking could accurately predict the substrates of the multidrug 
resistant protein. It appears that several aspects are important for daunorubicin analogs 
binding to MsbA: (1) The substitution pattern and stereochemistry of the tetracyclic ring 
and sugar moiety; (2) the hydrogen bond donor or acceptor capability of the substituent at 
C’-3 and C’-4.  The first sugar moiety of daunorubicin analogs plays more important role 
for the binding of MsbA than the second sugar in the disaccharide analogs.  
Molecular docking, cytotoxicity, and P-gp inhibition assay confirmed ADNR, 
ADNR-1 and ADNR-3 for averting P-gp binding and overcoming drug resistance. The 
replacement of C’-3-NH2 group with azido group not only abolished the hydrogen bond 
between the C’-3 of the sugar moiety of daunorubicin and MsbA, but also completely 
changed the overall conformation of DNR, and thus averted the binding to MsbA.  
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Cytotoxicity assays confirmed that these compounds showed high sensitivity against 
drug-resistant cancer cells (K562/Dox) with P-gp over-expression. P-gp inhibition assays 
indeed confirmed that these compounds averted P-gp binding and overcame P-gp-
mediated drug resistance.  
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Figures and Tables 
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Figure 1 
Structures of the 25 daunorubicin analogs with various sugar modifications as well as 
DNR, the parent compound. 
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Figure 2 
Daunorubicin (DNR) bound to MsbA.  DNR binds to the cavity between intracellular 
domain (ICD) and nucleotide binding domain (NBD) of MsbA.  Hydrogen bonds 
between DNR and MsbA are represented with orange lines. DNR is labeled in red color. 
Green ribbon represents MsbA protein. Critical amino acids in MsbA are labeled with 
numbers. 
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                     Figure 3 
DNR monosaccharide analogs bound to MsbA as compared to the docked structure of 
DNR (red color).  A. DNR-1 (purple color); B. DNR-4 (green color); C. DNR-5 (sienna 
color); and D. DNR-6 (blue color). Green ribbon represents MsbA protein. Critical amino 
acids in MsbA are labeled with numbers. The thin orange lines represent hydrogen bonds. 
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Figure 4 
DNR disaccharide analogs bound to MsbA as compared to the docked structure of DNR 
(red color).   A. DNR-D1 (silver color); B. DNR-D3 (yellow color); C. DNR-D4 (light 
blue color); and D. DNR-D6 (purple color). Green ribbon represents MsbA protein. 
Critical amino acids in MsbA are labeled with numbers. The thin orange lines represent 
hydrogen bonds. 
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Figure 5 
ADNR and ADNR-T1 bound to MsbA as compared to the docked structure of DNR (red 
color).  A. ADNR (dark blue color); B. DNR-T1 (light blue color); C. DNR-T2 (yellow 
color); and D. DNR-T4 (sienna color). Green ribbon represents MsbA protein. Critical 
amino acids in MsbA are labeled with numbers. The thin orange lines represent hydrogen 
bonds.
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Figure 6 
ADNR disaccharide analogs (non-P-gp substrates) bound to MsbA as compared to the 
 docked structure of DNR (red color).  A. ADNR-1 (light blue color); B. ADNR-3  
(yellow color); C. ADNR-6 (purple color). Green ribbon represents MsbA protein. 
 Critical amino acids in MsbA are labeled with numbers. The thin orange lines represent 
 hydrogen bonds. 
 
 
 
 
 
 
His107
Asp431
Asn436
His202
Cys315
DNR
ADNR-D3 
 
His107 
His202 
Asp431 
Asn436 
DNR 
ADNR-D1 
 
His107 
His202 
Asp431 
Asn436 
DNR 
ADNR-D6 
Cys315 
C
A B
Robert F. Battisti 
Page 41 of 48 
 
 
Figure 7 
ADNR disaccharide analogs (P-gp substrates) bind to MsbA as compared to the docked 
structure of DNR (red color).  A. ADNR-2 (gold color); B. ADNR-4 (purple color); C. 
ADNR-5 (brown color). Green ribbon represents MsbA protein. Critical amino acids in 
MsbA are labeled with numbers. The thin orange lines represent hydrogen bonds. 
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Figure 8 
Relative expression levels of MDR-1 mRNA in K562 and K562/DOX as normalized by 
the expression of beta-actin. 
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Figure 9 
P-gp inhibition assay by P-gp inhibitor (cyclosporine, CsA).  1 uM concentrations of the 
daunorubicin analogs were used in the presence (black bar) or absence (blank bar) of       
5 uM concentration of CsA. A. DNR monosaccharide analogs; B. DNR disaccharide 
analogs; and C. ADNR and ADNR disaccharide analogs.   
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Table 1 
Associated Binding Energies of Each Compound Binding to MsbA 
Energies Determined by Autodock 
 
 
Compound MsbA Associated Binding Energy 
DNR -7.92 kcal/mol 
DNR-1 -9.05 kcal/mol 
DNR-2 -8.80 kcal/mol 
DNR-3 -9.20 kcal/mol 
DNR-4 -8.13 kcal/mol 
DNR-5 -8.16 kcal/mol 
DNR-6 -7.50 kcal/mol 
DNR-D1 -11.0 kcal/mol 
DNR-D2 -7.8 kcal/mol 
DNR-D3 -11.2 kcal/mol 
DNR-D4 -8.61 kcal/mol 
DNR-D5 -11.1 kcal/mol 
DNR-D6 -11.0 kcal/mol 
DNR-D7 -10.3 kcal/mol 
DNR-D8 -10.9 kcal/mol 
ADNR +2.94 kcal/mol 
ADNR-T1 +3.35 kcal/mol 
ADNR-T2 +18.78 kcal/mol 
ADNR-T3 +18.64 kcal/mol 
ADNR-T4 +18.76 kcal/mol 
ADNR-1 +7.46 kcal/mol 
ADNR-2 -8.92 kcal/mol 
ADNR-3 +2.38 kcal/mol 
ADNR-4 -7.51 kcal/mol 
ADNR-5 -3.22 kcal/mol 
ADNR-6 +17.25 kcal/mol 
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Table 2. IC50 and drug resistance index (DRI) of 25 daunorubicin analogs in drug-
sensitive (K562) and drug-resistant leukemia cells (K562/Dox). 
 
 
 
 
Compound IC50 in K562 
 (nM) 
IC50 in K562/Dox  
(µM) 
Drug Resistance 
Index (DRI) 
DNR 16 >5 >320 
DNR-1 265 >5 >19 
DNR-2 >5000 >5 N/A 
DNR-3 >5000 >5 N/A 
DNR-4 104 >5 >48 
DNR-5 350 4 12 
DNR-6 >5000 >5 N/A 
DNR-D1 40 1.4 34 
DNR-D2 46 3.2 69 
DNR-D3 44 2.3 51 
DNR-D4 >5000 >5 N/A 
DNR-D5 21 1.1 52 
DNR-D6 >5000 >5 N/A 
DNR-D7 >5000 >5 N/A 
DNR-D8 31 2.4  79 
ADNR 75 0.37 5 
ADNR-T1 >5000 >5 N/A 
ADNR-T2 >5000 >5 N/A 
ADNR-T3 >5000 >5 N/A 
ADNR-T4 >5000 >5 N/A 
ADNR-1 788 1.9 2 
ADNR-2 287 >5 >17 
ADNR-3 278 0.28 1 
ADNR-4 225 >5 >22 
ADNR-5 448 1.6 4 
ADNR-6 650 1.4 2 
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